Important Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); enCore Energy Corp. (NASDAQ: EU); Fluor Corporation (NYSE: FLR); Fortrea Holdings, Inc. (NASDAQ: FTRE); and Ibotta, Inc. (NYSE: IBTA): Grabar Law Office is Investigating…
PHILADELPHIA, Nov. 18, 2025 (GLOBE NEWSWIRE) --
Cytokinetics, Inc. (NASDAQ: CYTK):
Grabar Law Office is investigating claims on behalf of shareholders of Cytokinetics, Inc. (NASDAQ: CYTK). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.
If you purchased Cytokinetics, Inc. (NASDAQ: CYTK) shares prior to December 27, 2023, and still hold shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. Please visit https://grabarlaw.com/the-latest/cytokinetics-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085.
WHY? As alleged in a recently filed federal securities fraud class action complaint, Cytokinetics, Inc. (NASDAQ: CYTK), through certain of its officers made materially false and misleading statements on to the market, Specifically, on March 10, 2025, Cytokinetics disclosed that the U.S. Food and Drug Administration ("FDA") had decided not to convene an advisory committee meeting to review the Company's New Drug Application ("NDA") for aficamten. On May 1, 2025, Cytokinetics announced that the FDA had extended the Prescription Drug User Fee Act action date for aficamten's NDA from September 26, 2025 to December 26, 2025 in order to review a Risk Evaluation and Mitigation Strategy ("REMS") submitted at the FDA's request after the initial NDA filing, thereby disclosing that the Company had not included a REMS in the original NDA. Then, on May 6, 2025, Chief Executive Officer Robert I. Blum acknowledged that Cytokinetics had multiple pre-NDA meetings with the FDA to discuss safety monitoring and risk mitigation but chose to submit the NDA without a REMS, relying on labeling and voluntary education materials. These misleading statements and delayed disclosures caused the company and its shareholders significant harm.
WHAT YOU CAN DO NOW: If you purchased Cytokinetics, Inc. (NASDAQ: CYTK) shares prior to December 27, 2023, and still hold shares today, you are encouraged to visit https://grabarlaw.com/the-latest/cytokinetics-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. $CYTK #Cytokinetics
enCore Energy Corp. (NASDAQ: EU):
Grabar Law Office is investigating claims on behalf of shareholders of enCore Energy Corp. (NASDAQ: EU). The investigation concerns whether certain officers and directors breached their fiduciary duties.
If you purchased enCore Energy Corp. (NASDAQ: EU) shares prior to March 28, 2024, and still hold shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. Please visit https://grabarlaw.com/the-latest/encore-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085.
WHY? According to an underlying securities fraud class action complaint, enCore Energy Corp. (NASDAQ: EU), through certain of its officers, made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, the Complaint alleges Defendants failed to disclose to investors: (1) that enCore lacked effective internal controls over financial reporting; (2) that enCore could not capitalize certain exploratory and development costs under GAAP; (3) that, as a result, its net losses had substantially increased; and (4) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
WHAT YOU CAN DO NOW: If you purchased enCore Energy Corp. (NASDAQ: EU) shares prior to March 28, 2024, and still hold shares today, you are encouraged to https://grabarlaw.com/the-latest/encore-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. $EU #encoreenergy
Fortrea Holdings, Inc. (NASDAQ: FTRE):
Grabar Law Office is investigating claims on behalf of shareholders of Fortrea Holdings, Inc. (NASDAQ: FTRE). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.
Current Fortrea Holdings, Inc. (NASDAQ: FTRE) shareholders who shares prior to July 3, 2023 and still hold shares today, can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to them whatsoever.
You are encouraged to visit https://grabarlaw.com/the-latest/fortrea-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085.
WHY? According to an underlying securities fraud class action complaint, Fortrea Holdings, Inc. (NASDAQ: FTRE), through certain of its officers, made materially false and misleading statements regarding the Company's business, operations, and prospects. Specifically, the Complaint alleges Defendants made false and/or misleading statements and/or failed to disclose that: (i) Fortrea overestimated the amount of revenue the Pre-Spin Projects were likely to contribute to the Company's 2025 earnings; (ii) Fortrea overstated the cost savings it would likely achieve by exiting the TSAs; (iii) as a result, the Company's previously announced EBITDA targets for 2025 were inflated; (iv) accordingly, the viability of the Company's post-Spin-Off business model, as well as its business and/or financial prospects, were overstated; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.
WHAT YOU CAN DO NOW: If you purchased Fortrea Holdings, Inc. (NASDAQ: FTRE) shares prior to July 3, 2023 and still hold shares today, you are encouraged to visit https://grabarlaw.com/the-latest/fortrea-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. $FTRE #Fortrea
Ibotta, Inc. (NYSE: IBTA):
Grabar Law Office is investigating claims on behalf of shareholders of Ibotta, Inc. (NYSE: IBTA). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.
If you purchased Ibotta, Inc. shares on or shortly after the company’s April 18, 2024 IPO, and still hold shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. Please visit https://grabarlaw.com/the-latest/ibotta-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085, to learn more.
WHY? A federal securities fraud class action complaint alleges that statements made in Ibotta Inc’s (NYSE: IBTA) Registration Statement issued in connection with Ibotta’s April 18, 2024 initial public offering were false and/or misleading when made because they did not properly warn investors of the risks concerning Ibotta’s contract with The Kroger Co. Kroger’s contract was at-will, and Ibotta failed to warn investors that a large client could cancel their contract with Ibotta without warning. Despite providing a detailed explanation of the terms of Ibotta’s contract with Walmart, there was not a single warning of the at-will nature of Kroger’s contract.
WHAT YOU CAN DO NOW: If you purchased Ibotta, Inc. (NYSE: IBTA) shares on or shortly after the company’s April 18, 2024 IPO, and still hold shares today, you are encouraged to visit https://grabarlaw.com/the-latest/ibotta-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. $IBTA #IBTA #Ibotta
Attorney Advertising Disclaimer
Contact:
Joshua H. Grabar, Esq.
Grabar Law Office
One Liberty Place
1650 Market Street, Suite 3600
Philadelphia, PA 19103
Tel: 267-507-6085
Email: jgrabar@grabarlaw.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
